Incite Health, Inc. Announces the Launch of ZEUS Scientific MTTT-2 ELISA System

Business News

DOYLESTOWN, PA — Incite Health, Inc., a CLIA-certified, CAP-accredited, high-complexity clinical laboratory specializing in immune system testing, announces the launch of a new paradigm in Lyme Disease testing, the ZEUS Scientific MTTT-2™ ELISA system.

The Zeus Modified Two-Tiered Testing (MTTT-2) ELISA system is an FDA-cleared assay that has been shown to reduce the number of missed clinically positive samples compared with the Standard Two-Tiered Testing (STTT) algorithm that relies on a second-tier immunoblot. Incite Health is offering the MTTT-2 Lyme testing algorithm, providing the highest levels of sensitivity and specificity available in Lyme antibody testing on the market today. The MTTT-2 uses a VlsE1/pepC10 polyvalent ELISA as the initial screen, followed by separate second-tier IgG and IgM confirmatory ELISAs; this delivers the highest sensitivity for early detection of Lyme without compromising specificity.

Recently, the CDC updated their recommendation to state that serologic assays using a second ELISA test are an acceptable alternative to assays that use an immunoblot as a second test.

Lyme Disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of an infected blacklegged tick. Lyme disease is the most reported vector-borne illness in the United States, and cases have been reported in all 50 states. The symptoms of Lyme Disease are highly variable and similar to those of several other diseases. The most common symptoms of Lyme Disease are fever, headache, fatigue, joint pain and reduced mobility, muscle pain, along with cognitive problems.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.